Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Lalezari

Showing results (91-100 of 128) with videos related to

Pageof 13
Sort By:
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Clinical Therapeutics|October 1, 2024
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19Harish Seethamraju, Otto O Yang, Richard Loftus, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari, Judith A Aberg, Laurene H Wang, et al.
The New England Journal of Medicine|September 7, 1995
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study GroupW L Drew, D Ives, J P Lalezari, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1995
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patientsK C Cundy, B G Petty, J Flaherty, et al.
Annals of Internal Medicine|February 15, 1997
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trialJ P Lalezari, R J Stagg, B D Kuppermann, et al.
Journal of Clinical Microbiology|November 14, 1997
Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assayD N Chernoff, R C Miner, B S Hoo, et al.
The New England Journal of Medicine|June 6, 1996
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study GroupS A Spector, G F McKinley, J P Lalezari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2016
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvirKris V Kowdley, David R Nelson, Jacob P Lalezari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.
Pageof 13

Showing results (91-100 of 128) with videos related to

Sort By:
Pageof 13
Antiviral Therapy|December 7, 2016
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trialMelanie Thompson, Jacob P Lalezari, Richard Kaplan, et al.
Clinical Therapeutics|October 1, 2024
A Randomized Placebo-Controlled Trial of Leronlimab in Mild-To-Moderate COVID-19Harish Seethamraju, Otto O Yang, Richard Loftus, et al.
Antimicrobial Agents and Chemotherapy|August 17, 2002
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV sheddingJacob P Lalezari, Judith A Aberg, Laurene H Wang, et al.
The New England Journal of Medicine|September 7, 1995
Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study GroupW L Drew, D Ives, J P Lalezari, et al.
Antimicrobial Agents and Chemotherapy|June 1, 1995
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patientsK C Cundy, B G Petty, J Flaherty, et al.
Annals of Internal Medicine|February 15, 1997
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trialJ P Lalezari, R J Stagg, B D Kuppermann, et al.
Journal of Clinical Microbiology|November 14, 1997
Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assayD N Chernoff, R C Miner, B S Hoo, et al.
The New England Journal of Medicine|June 6, 1996
Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study GroupS A Spector, G F McKinley, J P Lalezari, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 19, 2016
On-treatment HCV RNA as a predictor of sustained virological response in HCV genotype 3-infected patients treated with daclatasvir and sofosbuvirKris V Kowdley, David R Nelson, Jacob P Lalezari, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 20, 2025
Leronlimab Treatment for Multidrug-Resistant HIV-1 (OPTIMIZE): A Randomized, Double-Blind, Placebo-Controlled TrialJoseph C Gathe, Edwin Dejesus, Moti N Ramgopal, et al.
Pageof 13